3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
1230
Neoplasms
1040
Carcinoma, Non-Small-Cell Lung
757
Prostatic Neoplasms
697
Colorectal Neoplasms
598
Lung Neoplasms
578
Pancreatic Neoplasms
403
Leukemia, Myeloid, Acute
399
Neoplasm Metastasis
391
Ovarian Neoplasms
373
Multiple Myeloma
373
Stomach Neoplasms
319
Carcinoma, Hepatocellular
304
Melanoma
284
Brain Neoplasms
281
Recurrence
280
Squamous Cell Carcinoma of Head and Neck
269
Head and Neck Neoplasms
240
Endometrial Neoplasms
236
Glioblastoma
235
Triple Negative Breast Neoplasms
230
Precursor Cell Lymphoblastic Leukemia-Lymphoma
226
Lymphoma
226
Uterine Cervical Neoplasms
225
Sarcoma
202
Hematologic Neoplasms
201
Urinary Bladder Neoplasms
197
Esophageal Neoplasms
192
Carcinoma, Renal Cell
191
Lymphoma, Non-Hodgkin
177
Interventions
ofatumumab
1
daratumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
×
1 year
×
Clear all
NCT06867991
2025-07-15
RADIA
The First People's Hospital of Changzhou
Phase 3
Recruiting
200 enrolled